Cormorant Asset Management’s Abeona Therapeutics ABEO Stock Holding History

Cormorant Asset Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-8,000	Closed	-$452K	–	68
2019 Q3	$452K	Sell	8,000 -6,000	-43%	-$449K	0.03%	72
2019 Q2	$1.67M	Sell	14,000 -2,000	-13%	-$335K	0.1%	67
2019 Q1	$2.94M	Sell	16,000 -3,541	-18%	-$633K	0.2%	58
2018 Q4	$3.49M	Sell	19,541 -459	-2%	-$100K	0.28%	57
2018 Q3	$6.4M	Sell	20,000 -1,976	-9%	-$701K	0.42%	45
2018 Q2	$8.79M	Hold	21,976	–	–	0.65%	40
2018 Q1	$7.88M	Sell	21,976 -1,024	-4%	-$380K	0.59%	31
2017 Q4	$9.11M	Buy	23,000 +7,000	+44%	+$2.89M	0.95%	27
2017 Q3	$6.82M	Hold	16,000	–	–	1.2%	28
2017 Q2	$2.56M	Hold	16,000	–	–	0.42%	51
2017 Q1	$2M	Sell	16,000 -4,000	-20%	-$516K	0.29%	61
2016 Q4	$2.42M	Buy	+20,000	New	+$3.13M	0.33%	58

Other funds holding ABEO

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Cormorant Asset Management's ABEO Position: Q4 2019 in Review

Cormorant Asset Management sold out of Abeona Therapeutics (ABEO) in Q4 2019, closing a stake of 8,000 shares — an estimated $452K sold.

Cormorant Asset Management first reported a position in ABEO in Q4 2016 and held it in 12 quarters. The position peaked at $9.11M in Q4 2017. 87 funds tracked by Wall St. Rank hold ABEO as of Q4 2019.

Cormorant Asset Management reported no remaining Abeona Therapeutics position as of Q4 2019 after selling out during the quarter.
Cormorant Asset Management sold 8,000 Abeona Therapeutics shares in Q4 2019, an estimated $452K.
Cormorant Asset Management first reported a position in Abeona Therapeutics in Q4 2016 and held it in 12 quarters.
Cormorant Asset Management's Abeona Therapeutics position peaked at $9.11M in Q4 2017.
87 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2019.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.